G

GE Healthcare

Imaging, monitoring, and healthcare IT solutions

Clinical Product & Collaboration Strategy Manager

Full-TimeUpdated on 10/23/2026
No salary listed
Senior
Bachelor's
Waukesha, WI, USA
In PersonRelocation assistance is provided.
Biology & Biotech
No H1B Sponsorship

About the job

Requirements
  • A bachelor's degree in healthcare technology, engineering, a clinical field, or a related field is required.
  • At least 7 years of experience in healthcare technology, medical device, software, or digital health product development, clinical research, medical imaging, imaging informatics, or related healthcare technologies is required.
  • Experience leading complex cross-functional initiatives involving product development and external clinical partners is required.
  • Experience building and managing strategic collaborations with healthcare providers, academic institutions, or innovation partners is required.
  • Demonstrated ability to communicate and influence effectively across clinical, technical, business, and executive stakeholders, internally and externally, is required.
Responsibilities
  • Collaborate with Business Leadership and cross-functional teams to define a strategy for delivering innovation, evaluation, and evidence across AIS Digital product portfolios, based on business strategy, product portfolios, roadmaps, innovation plans, and clinical and technical expertise.
  • Lead portfolio prioritization and resource allocation decisions to align research investments with business priorities and measurable impact.
  • Identify and develop clinical and academic partnerships suited for GE HealthCare research and co-creation, assessing partner strengths, collaboration interests, and potential contribution to the AIS Digital research strategy.
  • Develop and maintain a process to assess and respond to incoming research proposals.
  • Partner with Clinical Project Managers and cross-functional teams to ensure research, evaluation, and co-creation initiatives are executed successfully and deliver intended business, product, and customer outcomes.
  • Drive adoption and utilization of research outputs across product management, engineering, marketing, and commercial teams.
  • Ensure that the portfolio of research activities delivers value to the business.
Desired Qualifications
  • Clinical expertise in one or more imaging modalities, or technical expertise in healthcare IT, imaging informatics, and enterprise imaging environments.
  • Knowledge of GE HealthCare's Quality Management System or GE HealthCare products.
  • Experience developing research strategies and portfolios that influence product development, evidence generation, or business decisions.
  • Demonstrated understanding and experience with GXP practices, research or device manufacturer regulations, research processes, or NPI cycles.

About the company

GE Healthcare Systems provides medical technologies and digital infrastructure to improve diagnosis, treatment, and monitoring of patients. Its products include imaging systems, mobile diagnostic devices, patient monitoring tools, and healthcare IT software that work together as hardware, software, and services to support hospitals, clinics, and researchers. The company differentiates itself with a large, integrated ecosystem, strong focus on AI analytics, and a global service network backed by substantial R&D investment. Its goal is to improve patient outcomes and the efficiency of healthcare delivery by enabling accurate diagnoses, effective treatments, and scaled operations.

Company Size

1-10

Company Stage

IPO

Headquarters

Chicago, Illinois

Founded

1892

Get referred to GE Healthcare

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 orders rose 11% and backlog reached a record $23.9 billion.
  • CareIntellect for Operations launched September 2026 with Duke Health and Queen's Health Systems.
  • CE mark and FDA progress for Photonova Spectra expand 2026-2027 commercial momentum.

What critics are saying

  • FDA logged multiple 2026 Class 2 recalls, including AW Server and telemetry systems.
  • Patient Care Solutions remained weak in Q2 2026; management is reviewing a sale.
  • SOFIE closes only after 2027 regulatory approvals; PET supply integration can slip badly.

What makes GE Healthcare unique

  • GE HealthCare combines imaging hardware, radiopharmaceuticals, and workflow software across hospitals.
  • Photonova Spectra and Vivid 2026 show premium innovation plus AI-enabled clinical automation.
  • SOFIE's 21 cyclotrons extend GE HealthCare into radiotracer manufacturing, not just scanners.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Tuition Reimbursement
  • Relocation Assistance

Company News

Yahoo Finance
Oct 23rd, 2026
Cash-rich stocks: Clean Harbors worth watching, UPS and GE HealthCare best avoided

StockStory has named one cash-generating stock worth a closer look and two it would avoid, arguing that strong cash flow does not always mean strong returns. Clean Harbors (NYSE:CLH) is the pick. Its revenue grew 13.5% a year over five years, and earnings per share rose 21.6% a year, helped by share buybacks. Its free cash flow margin is 8.8%, up 5.9 percentage points over five years. The shares trade at $320.91, or 30.7x forward earnings. StockStory would steer clear of United Parcel Service (NYSE:UPS) and GE HealthCare (NASDAQ:GEHC). UPS sales were flat over five years while earnings per share fell 8.4% a year. GE HealthCare faces projected sales growth of 4.4% and a 1.7-point drop in adjusted operating margin.

Associated Press
Oct 20th, 2026
GE HealthCare launches five-institution global trial of StarGuide GX theranostics SPECT/CT system

GE HealthCare has launched a clinical evaluation program for StarGuide GX, its next-generation digital 4D SPECT/CT system. Five institutions across three continents will take part. They are Hadassah Medical Center and Rambam Health Care Campus in Israel, Mayo Clinic in the US, Oncopole Claudius Regaud in France, and Peking University First Hospital in China. Each will assess image quality, quantitative performance, dynamic imaging, and workflow, and give feedback to guide the system's development. StarGuide GX uses dual-sided cadmium zinc telluride detectors and a dual-collimator design meant to remove manual collimator changes. It also uses NVIDIA RTX accelerated computing for image reconstruction. The system received CE Mark in November 2025 and is on sale in select EU states. Its US Food and Drug Administration 510(k) clearance is pending.

Yahoo Finance
Oct 19th, 2026
GE HealthCare launches LOGIQ Focus ultrasound with AI tools, 26% faster scans

GE HealthCare has launched LOGIQ Focus, a new general imaging ultrasound system in its LOGIQ family. The company announced the product in Chicago on October 19, 2026. The system runs on cSound Architecture and pairs high-definition imaging with AI-enabled tools. One of them, Auto Preset Assistant, detects the anatomy being scanned and activates the matching preset, saving up to five clicks per exam. In a third-party study, 90% of participants rated its image quality as excellent. The system was 26% faster than the predicate system. LOGIQ Focus is 510(k) cleared and CE Marked. GE HealthCare expects it and several other new products to add 1% to 2% to revenue growth, following more than $5 billion in innovation investment since 2023.

Business Wire
Oct 5th, 2026
GE HealthCare to acquire SOFIE Biosciences for $945M to expand US radiopharmaceutical supply

GE HealthCare has agreed to acquire SOFIE Biosciences, a US-based contract manufacturer of PET radiopharmaceuticals, for $945 million in cash. The deal with seller Trilantic North America is expected to close in the first half of 2027, subject to regulatory approvals. SOFIE Biosciences operates 15 contract manufacturing sites with 21 cyclotrons across the US, plus a theranostics-focused development and manufacturing facility. The acquisition establishes GE HealthCare's presence in the time-critical "final mile" of US PET radiopharmaceutical supply. The PET radiopharmaceutical market is expanding rapidly with approximately 20 PET radiotracers and over 30 radiotherapeutics currently under development. SOFIE Biosciences' portfolio includes a Phase III FAPI asset for which GE HealthCare already holds non-US rights. GE HealthCare estimates the transaction will be accretive to revenue growth, earnings margin, and earnings per share in the first full year of ownership.

PR Newswire
Sep 30th, 2026
AsiaMedic first in ASEAN to deploy GE HealthCare's MR31 deep learning MRI platform

AsiaMedic has become the first site in ASEAN to implement MR31, GE HealthCare's latest generation MRI platform featuring deep learning technology. The Singapore-based imaging centre is among the earliest adopters in Asia Pacific. MR31 incorporates deep learning technologies that reduce scan times and enable detailed examinations across neurological, musculoskeletal and nerve imaging. Sonic DL for 3D delivers up to 12 times scan acceleration, reducing examination times across brain, spine, orthopaedic and body scans. The platform also supports high-quality prostate MRI imaging. AIR Recon DL Phase Correction provides improved visualisation of clinically significant lesions, whilst high-resolution T2-weighted imaging aids lesion localisation for prostate fusion biopsy planning. Shorter scan times mean reduced patient time in scanners and may help decrease repeat examinations caused by movement.